BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 81.72 |
| Open | 81.14 |
| Bid | 80.92 x 200 |
| Ask | 85.49 x 100 |
| Day's range | 80.74 - 81.95 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,535,772 |
| Market cap | 15.386B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 76.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
- GuruFocus.com
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
- Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
© 2024 Yahoo. All rights reserved.